Peptide Reference
Melanotan I
Melanotan I (Afamelanotide)
The first-generation melanocortin analog developed for tanning and erythropoietic protoporphyria. Afamelanotide is FDA-approved under the brand name Scenesse.
Status
approved
Category
sexual
Typical cost
$15,000-20,000/year (Scenesse)
Mechanism
Activates melanocortin-1 receptors to stimulate melanin production. Longer half-life than Melanotan II with more gradual tanning effects and fewer side effects.
Potential benefits
- FDA-approved indication
- Melanoma prevention in EPP
- Gradual natural-looking tan
- Fewer side effects than MT2
- Long-acting implant
Reported side effects
- Nausea (less than MT2)
- Facial flushing
- Appetite changes
- Implant site reactions
Common dosing references
subcutaneous implant
16mg · Every 60 days
Ongoing
Research notes
Scenesse FDA approval for EPP
2019
FDA approved for prevention of phototoxic reactions in EPP
Regulatory and sourcing notes
FDA-approved as Scenesse for erythropoietic protoporphyria. Not approved for cosmetic tanning.
Prescription only. Administered as subcutaneous implant by healthcare provider. Not available as research peptide.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides